
American Association for Cancer Research
- AbstractMetastasis remains a leading cause of mortality in patients with esophageal squamous cell carcinoma (ESCC), underscoring the urgent need to elucidate the molecular mechanisms driving disease progression. In this study, we delineated that zinc finger BED-type containing 2 (ZBED2), a zinc finger protein, correlates with inferior survival outcomes and metastasis in patients with ESCC. ZBED2 […]
- AbstractThe immune system can eradicate cancer, but various immunosuppressive mechanisms active within a tumor curb this beneficial response. However, unraveling the effects of multimodal interactions between tumor and immune cells and their contributions to tumor control using an experimental approach alone is time and resource intensive. To identify the critical immunologic features associated with tumor […]
- Hepatocellular carcinoma (HCC) typically arises within fibrotic, mechanically rigid microenvironments where matrix stiffness directly drives primary tumor proliferation and invasion. However, whether and how tumor cells retain these mechanical adaptations upon disseminating to softer metastatic sites has remained unclear. In this issue of Cancer Research, Luo and colleagues demonstrate that HCC cells retain a “mechanical […]
- AbstractCasein kinase 1α (CK1α) is a multifunctional serine/threonine kinase, serving as an upstream regulator of the p53 pathway and a potential therapeutic target for acute myeloid leukemia (AML). Small-molecule degraders show preclinical promise in AML by selectively degrading target proteins. In this study, we developed and evaluated PinA1, a molecular glue degrader targeting CK1α, in […]
- Metastatic cancer cells must adapt to the physical properties of distant tissues, yet the consequences of such mechanical adaptation for immune surveillance remain poorly understood. In Immunity, Elbanna and colleagues reveal an unexpected trade-off between mechanical fitness and immune vulnerability: Environmental rigidity induces cancer cell stiffening, enabling robust colonization of rigid bone in the absence […]
- AbstractPurpose:Tinengotinib, a multikinase inhibitor targeting Aurora kinases A/B, fibroblast growth factor receptors (FGFRs) 1 to 3, vascular endothelial growth factor receptor 2, and Janus kinases 1 to 2, was evaluated in this phase Ib/II study to assess safety, pharmacokinetics (PK), efficacy, and genomic correlates of response and resistance in patients with advanced solid tumors.Patients and […]
- AbstractPurpose:Microsatellite-stable metastatic colorectal cancer (MSS mCRC) has limited treatment options and responds poorly to conventional immunotherapy. We report extended follow-up results from a fully enrolled, phase Ib cohort evaluating botensilimab [BOT; Fc-enhanced anti–cytotoxic T-lymphocyte–associated protein 4 (CTLA-4)] plus balstilimab [BAL; anti–programmed cell death protein 1 (PD-1)] in patients with MSS mCRC and no active liver […]
- AbstractPurpose:In locally advanced resectable squamous cell carcinoma of the head and neck (SCCHN), patients treated with neoadjuvant chemotherapy with major pathologic response (MPR) or pathologic complete response (pCR) have overall survival (OS) rates superior to those of patients with poorer pathologic responses. To improve efficacy, we added the PD-1 inhibitor nivolumab to neoadjuvant chemotherapy and […]
- AbstractPurpose:Signal transducer and activator of transcription 3 (STAT3) is important in promoting a pro-oncogenic tumor microenvironment. This first randomized trial of a STAT3-targeting antisense oligonucleotide with pembrolizumab assessed whether this first-line combination would improve outcomes compared with pembrolizumab alone in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).Patients and Methods:This multicenter, randomized, open-label, controlled […]
- AbstractPurpose:Treatment intensification with androgen receptor pathway inhibitors (ARPI) has become the standard of care for patients with metastatic prostate cancer (mPC). However, there remains an unmet need to identify biomarkers for treatment resistance. In this study, we identify SPEN inactivation as a driver of ARPI resistance.Experimental Design:Preclinical studies were performed using LNCaP and VCaP cell […]
Cancer.gov
- In a new National Institutes of Health (NIH)-funded study, scientists at Cleveland Clinic discovered that hormones associated with male development may play a key role in limiting the growth of brain tumors in men. The research team found that the loss of androgen hormones, such as testosterone, in a preclinical model of glioblastoma drove tumor […]
- In a National Institutes of Health (NIH)-funded study, researchers developed a cancer assessment tool that can identify high-risk patients and the tumor cells linked to that risk. The model, called scSurvival, uses a machine learning framework designed to analyze large-scale data at single-cell resolution.
- In a new study, funded in part by the National Institutes of Health (NIH), researchers have uncovered a molecular mechanism that could explain how chronic gut inflammation may increase the risk of colorectal cancer. By simulating chronic colitis in mice and tracking the colon’s response during inflammation and recovery, scientists demonstrated that these changes increased […]
- National Institutes of Health (NIH)-supported investigators have developed a blood test to find pancreatic ductal adenocarcinoma, one of the deadliest forms of cancer. The new test could improve survival rates from pancreatic cancer, which tends to be diagnosed at late stages when therapy is less likely to be effective. The findings were published in Clinical […]
- Using lung cancer biospecimens from the Sherlock-Lung study, an international team led by National Institutes of Health (NIH) researchers, identified key factors that drive tumor evolution and influence outcomes. Overall, the findings, published Dec. 10, 2025, in Nature, describe a previously unknown origin of some aggressive lung cancers.
JAMA Oncology – Current Issue
- This Viewpoint discusses recent US Food and Drug Administration (FDA) decisions regarding oncology drug trials for refractory melanoma and their potential negative impacts on the US regulatory environment.
- This Viewpoint discusses the strong connection between quality improvement and leadership development.
- This retrospective modeling and validation study uses clinical trial data to develop mathematical biomarkers that predict outcomes of patients with prostate cancer undergoing adaptive therapy.
- To the Editor Pinheiro and colleagues provide important evidence that adult T-cell leukemia/lymphoma (ATLL) is concentrated among non-Hispanic Caribbean-born US residents. However, the article moves from adult cancer burden to a maternal screening claim that its data cannot directly support. The Key Points ask whether ATLL incidence in this population reaches levels that “justify maternal” […]
- This Viewpoint the regulatory problem of how to design clean trials that regulators seek as the field of oncology becomes more therapeutically sophisticated.
ClinicalTrials.gov – Cancer
- Conditions: Retroperitoneal Neoplasms Sponsors: The First Hospital of Jilin University Recruiting
- Conditions: Cancer; Precancerous Lesion; Carcinoma in Situ Interventions: Other: MCED Sponsors: Sun Yat-sen University Not yet recruiting
- Conditions: Colorectal Cancer Liver Metastases (CRLM); ctDNA Interventions: Combination Product: Circulating Tumor DNA Methylation Testing; Other: Conventional Postoperative Treatment Strategy Sponsors: Fudan University Recruiting
- Conditions: Diffuse Large B-Cell Lymphoma (DLBCL) Interventions: Drug: Lenalidomide; Drug: Bruton's tyrosine kinase inhibitor; Drug: Chidamide Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting
- Conditions: Prostate Cancer; PI-RADS 3 Prostate Lesion Interventions: Diagnostic Test: PET Imaging with Flotufolastat F 18 Sponsors: SimonMed Imaging; Blue Earth Diagnostics Not yet recruiting
STAT!Ref Evidence Alerts
- Pain. 2026 Oct 13. doi: 10.1097/j.pain.0000000000004132.
- J Thromb Haemost. 2026 Sep 12:S1538-7836(26)00565-9. doi: 10.1016/j.jtha.2026.09.005.
- JAMA Oncol. 2026 Sep 17. doi: 10.1001/jamaoncol.2026.3626.
- J Clin Oncol. 2026 Sep 3:JCO2502974. doi: 10.1200/JCO-25-02974.
- Eur Heart J. 2026 Jul 28:ehag562. doi: 10.1093/eurheartj/ehag562.

ACCEL – Professional Insight, always within reach.
Professional Development Insights are part of the Salinas Valley Health’s Medical Staff Services and for our Physicians/APPs, we offer ACCEL.
ACCEL is a professional development platform created exclusively for Physicians and APPs at Salinas Valley Health. It offers expert-led content on the non-clinical aspects of medical practice — the things that shape daily work but rarely fit into formal training. Articles, Book Summaries, Videos, Audio/Visual… just for you!
- Provided at no cost to Medical Staff members
- Optional and self-directed
- Private — not tracked or reported
- Available on any computer or mobile device
- Login and password provided by Medical Staff Services
Here are the Just In insights…
*For providers of Salinas Valley Health, if you need access to any particular article referred to in these news feeds, please email Library@SalinasValleyHealth.com

